Drugs / JNJ26489112
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01949610 | Jan → Mar 2010 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01114698 | Mar 2011 → Jan 2012 | depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00579384 | Oct 2007 → Jul 2008 | photosensitive epilepsy | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-26489112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00579384 ↗ |
| Modality | Small molecule | — CHEMBL3092995 ↗ |
| Route | Oral | “Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.” NCT00579384 ↗ |